The agreement adds a new $50 million tranche available at the company’s discretion, contingent on hitting specific development milestones for its lead candidates, zeleciment rostudirsen and zeleciment basivarsen. Furthermore, the final potential loan segment grew by $25 million, creating a total pool of $75 million available upon request, subject to Hercules Capital’s approval.

Following this transaction, Dyne has drawn a total of $200 million across three tranches. The company retains access to an additional $200 million in potential future funding, maintaining a flexible balance sheet as it continues its research into exon 51 Duchenne muscular dystrophy and myotonic dystrophy type 1.